---
title: "Obefazimod (ABX464) in Ulcerative colitis: Executive summary: Disease burden"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Disease burden. Topics: Summary: epidemiology and natural history, Summary: long-term morbidity and humanistic burden, Summary: economic burden, and Summary: limitations of current therapies. 4 evidence topics quoted from 33 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary/disease-burden"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Ulcerative colitis

<a id="topic-1.1.1-1"></a>

### Summary: epidemiology and natural history

In a U.S. study, the age-, sex-, and insurance-standardized prevalence of ulcerative colitis was 378 per 100,000 population (95% CI 375 to 382); extrapolated to the 2020 census, the authors estimated 1.253 million Americans with ulcerative colitis. In the same study, the incidence of ulcerative colitis (6.3, 95% CI 6.1 to 6.6) was higher than that of Crohn's disease (4.1, 95% CI 3.9 to 4.3) and peaked in the third decade of life. ICER reports approximately 160,000 people with ulcerative colitis (0.64%) among 25 million Medicare fee-for-service beneficiaries. Worldwide, the prevalence of ulcerative colitis was estimated at 5 million cases in 2023, and “the incidence is increasing worldwide.”

ICER's 2020 report cites the Crohn's and Colitis Foundation for the statement that approximately 22% of patients with ulcerative colitis “have moderate-to-severe disease activity in a given year”, and in a Copenhagen cohort diagnosed in 2003 to 2004, early disease activity was moderate-to-severe in 24%. In a company estimate, Abivax states that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and that U.S. advanced therapy use reached approximately 271,000 patients in 2025. Among 3,893 patients with newly diagnosed ulcerative colitis, cumulative 5-year use of advanced therapy was 29% (95% CI 27 to 31), and 38% (95% CI 34 to 41) among patients diagnosed in 2019 to 2023.

The disease course is most often relapsing and remitting. A review reports a cumulative risk of relapse of 70% to 80% at 10 years and an aggressive course in about 10% to 15% of patients. At diagnosis, a median of 40.1% of patients had left-sided colitis, 30.5% extensive colitis, and 29.4% proctitis. In the cohort of 3,893 newly diagnosed patients, the cumulative 5-year risk of IBD-related hospitalization was 11% (95% CI 10 to 12) and of colectomy 5.7% (95% CI 4.8 to 6.7), with a 5-year colectomy risk of 4.2% among patients diagnosed in 2019 to 2023 against 6.7% among those diagnosed in 2007 to 2012. Across 26 studies, 1-, 5-, and 10-year colectomy risks were 4.0%, 8.8%, and 13.3%, and contemporary risks were 2.8%, 7.0%, and 9.6%. A review states that “10-20% of patients still require proctocolectomy for medically refractory disease.”

Sources differ on mortality. The all-cause summary standardized mortality ratio across inception cohort and population cohort studies was 1.19 (95% CI 1.06 to 1.35), with increased mortality from colorectal cancer, pulmonary disease, and nonalcoholic liver disease and decreased mortality from cardiovascular disease, and a review reports life expectancy of approximately 80.5 years for females and 76.7 years for males, “approximately 5 years shorter than people without UC.” Another review states that ulcerative colitis “has not been associated with an increased mortality, as compared to the general population, except in one cohort”.

Source: [Lewis et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10592313/); [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [Le Berre et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37573077/); [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf); [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Tsai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8934200/); [Bewtra et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3755276/); [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/)

<a id="topic-1.1.1-2"></a>

### Summary: long-term morbidity and humanistic burden

A review states that the risk of colorectal cancer after 20 years of disease duration is 4.5% and that people with ulcerative colitis have a 1.7-fold higher risk than the general population. In a cohort study, incident colorectal cancer occurred at 1.29 per 1000 person-years in the ulcerative colitis cohort and 0.82 per 1000 person-years in reference individuals (HR 1.66, 95% CI 1.57 to 1.76); during 2013 to 2017 (Sweden only), the HR was 1.38 (95% CI 1.20 to 1.60). Across 52 studies reporting on 352 454 patients, the prevalence of at least one joint, ocular, or skin extraintestinal manifestation was 27% in ulcerative colitis. Among patients with newly diagnosed ulcerative colitis, the cumulative 5-year risk of serious infection was 10.2% (95% CI 9.1 to 11.4). Patients with ulcerative colitis had a 1.8 times higher risk of work disability (95% CI 1.4 to 2.3) than the general population.

Among 289 U.S. and 1037 EU5 participants with moderate-to-severe ulcerative colitis, those with active disease reported lower EQ-5D health state utilities (adjusted means 0.87 in the U.S. and 0.78 in the EU5) than those in remission (0.92 and 0.91). In a survey of 2100 participants across 10 countries, participants reported a mean of 4.3 flares (SD 7.4) in the past year, 84% of patients with moderate to severe disease reported ulcerative colitis to be “mentally exhausting”, 65% felt that ulcerative colitis controlled their life, and 21% and 15% reported a diagnosis of anxiety or depression, respectively. In a survey of 200 U.S. and 556 European participants, 45.0% of U.S. and 37.0% of European patients reported wearing diapers, pads, or protection at least once a week in the past 3 months due to fear or anticipation of fecal urge incontinence, and among patients who had experienced bowel urgency, 78.0% of U.S. and 77.2% of European patients reported that it negatively affected work or school. Across 77 studies including 30 118 patients with inflammatory bowel disease, the pooled prevalence of anxiety symptoms was 32.1% and of depression symptoms 25.2%, and both were higher in active than in inactive disease.

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/); [Olén et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31929014/); [Kilic et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37042969/); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Fumery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658168/); [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/); [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/); [Travis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144997/); [Barberio et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33721557/)

<a id="topic-1.1.1-3"></a>

### Summary: economic burden

ICER's 2020 report states that the economic burden of ulcerative colitis in the United States ranges “between an estimated $15-32 billion per year”, and ICER's 2026 report cites recent estimates of $50 billion per year for inflammatory bowel disease. In MarketScan insurance claims data for 85,755 patients with ulcerative colitis, the lifetime incremental cost averaged $230,102 for a diagnosis at any age and the lifetime total cost was $405,496 (2016 U.S. dollars, discounted at 3% per annum). Among 52,782 patients with inflammatory bowel disease (29,062 with ulcerative colitis), direct costs were $22,987 per member per year against $6956 for controls, and mean costs were $26,555 in the first year after diagnosis.

Costs were higher with treatment failure and with chronic corticosteroid use. In one analysis, 75% of patients experienced treatment failure within the first 12 months, and mean all-cause costs were $74 995 in the treatment failure cohort against $56 169 in the persistent cohort. Among 3562 patients initiating advanced therapy, 12.2% had a UC-related hospitalization within 12 months and mean unadjusted UC-related costs were $42,579. Mean all-cause total costs per patient per year were $73,491 for chronic against $58,884 for nonchronic corticosteroid users among targeted treatment initiators, and $39,335 against $21,271 among conventional therapy initiators. The median index hospitalization cost of nonelective colectomy or rectal resection was $40,300 (IQR $26,400 to $65,000) among an estimated 10,280 patients.

Among 282 patients with ulcerative colitis, annual indirect costs due to total work impairment rose from $4348 per patient per year in remission to $24 283 per patient per year in moderately-to-severely active disease. The authors of a U.S. and EU5 survey estimated that the observed work impairment would equate to $15,400 in lost wages per employed patient with ulcerative colitis per year in the United States. In the survey of 2100 participants across 10 countries, 74% of employed patients reported work absence because of ulcerative colitis, missing a mean of 8.1 working days in the past 12 months. Patients with inflammatory bowel disease paid $2213 against $979 in out-of-pocket costs per year compared with patients without it. In a review of 25 studies (12 eligible for meta-analysis), the pooled prevalence of caregiver burden was 470 per 1000 carers, and in a study of 102 participants with inflammatory bowel disease and their caregivers, 39% of caregivers experienced burden.

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf); [ICER special assessment of Entyvio to inform CMS negotiation (2026)](https://icer.org/wp-content/uploads/2026/03/Entyvio_Final-Evidence-Report_For-Publication_030326.pdf); [Lichtenstein et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31326606/); [Park et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7534391/); [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094759/); [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/); [Zhdanava et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10839463/); [Ng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583900/); [Ding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9802455/); [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/); [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/); [Dadoo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13312674/); [Zand et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7302133/)

<a id="topic-1.1.1-4"></a>

### Summary: limitations of current therapies

A review states that “the highest response to these treatments ranges from 30% to 60% in clinical trials.” The ACG 2025 guideline states that up to one-fifth of patients receiving anti-TNF agents may not respond initially and that “an additional 10%–15% may lose response every year”. The ECCO 2026 guideline states that 10% to 13% of patients on anti-TNFs lose response annually and that 40% of patients on vedolizumab maintenance therapy lose response, of whom approximately half recapture response with dose escalation. Among 3562 patients initiating advanced therapy, 83.0% had used steroids in the preceding 12 months and 47.8% remained steroid-free after 12 months. The Xeljanz label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. The Velsipity label requires assessments before initiation and lists myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure experienced in the last 6 months. Abivax states that biological agents require injections or intravenous infusions, “resulting in patient inconvenience and burden, which often negatively impacts patient compliance.”

Obefazimod is investigational, and Abivax states that it “has not yet been approved for commercial use in any jurisdiction.” No FDA application has been submitted; Abivax states that it “remains on track to submit its first NDA for obefazimod by the end of 2026.” The results of the ABTECT trials come from company press releases, filings, and congress presentations, and for the two induction trials also from ClinicalTrials.gov results first posted on September 10, 2026; no peer-reviewed full publication of the ABTECT trials exists as of November 2026.

Source: [Gros and Kaplan (2023)](https://pubmed.ncbi.nlm.nih.gov/37698559/); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617); [Long et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7216775/); [Xeljanz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203214s042lbl.pdf); [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/); [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod); [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203); [ClinicalTrials.gov NCT05507216](https://clinicaltrials.gov/study/NCT05507216)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
